Treatment with Minocycline and Kampo Medicine (Kami-Kihi-To and Saiko-Keishi-To) for COVID-19 and Long COVID
Masashi Ohe
doi:10.20944/preprints202507.1139.v1
Coronavirus disease 2019 (COVID-19) remains a global threat to human health because of its sporadic prevalence despite the development of COVID-19 vaccines and several drugs such as remdesivir and molnupiravir. Moreover, long COVID has become another global issue. No standard treatment has been established for long COVID. Therefore, finding quickly effective and low-priced drugs against COVID-19 and long COVID-19 and conducting clinical trials on these drugs remains crucial for global health. Drug repurposing is a well-known strategy for redeploying existing licensed drugs for newer indications, enabling the shortest possible transition from bench to bed side. Regarding existing licensed drugs for COVID-19, tetracycline has been administered since the beginning of 2020 due to its efficacy in inhibiting COVID-19 and its anti-inflammatory effects. Neuroinflammation associated with microglia in the central nervous system is considered one of the pathophysiologies of long COVID. Further, tetracycline is expected to be efficacious against long COVID because it inhibits microglial activity. Recently, minocycline has been efficacious against long COVID. Considering other existing licensed drugs for COVID-19, Kampo medicine, which is a traditional Japanese medicine, has been prescribed during the COVID-19 pandemic due to its efficacy in inhibiting severe acute respiratory syndrome corona virus 2 and its anti-inflammatory effects. Recently, Kampo medicine has been effective for long COVID. Multidrug treatment is effective because of the synergistic effects associated with the different mechanisms of action of the concerned drugs. Therefore, a combination of minocycline and Kampo medicine may be more efficacious against COVID-19 and long COVID.
References
Ballering, Van Zon, Hartman, Rosmalen, Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study, The Lancet
Bharadwaj, Lee, Dwivedi, Kang, Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calcula tions, Life Sci
Cheng, Ng, Chiang, Lin, Antiviral effects of saikosaponins on human coronavirus 229E in vitro, Clin Exp Pharmacol Physiol
Fazil, Nikhat, Therapeutic and palliative role of an Unani herbal decoction in COVID-19 and similar respiratory viral illnesses: Phytochemical & pharmacological perspective, J. Ethnopharmacol
Filho, Gonçalves, Mottin, Repurposing of tetracyclines for COVID-19 neurological and neuropsychiatric manifestations: a valid option to control SARS-CoV-2-associated neuroinflammation?, J Neuroimmune Pharmacol
Gironi, Damiani, Zavattaro, Tetracyclines in COVID-19 patients quaran tined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses, Dermatol Ther
Gong, Zhu, Chen, The anti-depression effect of angelicae sinensis radix is related to the pharmacological activity of modulating the hematological anomalies, Front Pharmacol
Itoh, Tsutani, Iwasaki, Potential of Favipiravir and Minocycline Combination Therapy for COVID-19, Re: GEN Open
Jeon, Park, Park, An experimental study of effect on brain damage and neuroprotective effect of angelicae gigantis radix extract against cerebral ischemia in rats, Korea J Herb
Kakimoto, Nomura, Nazmul, In vitro suppression of SARS-CoV-2 infection by existing kampo formulas and crude constituent drugs used for treatment of common cold respiratory symptoms, Front Pharmacol
Miwa, Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study, eNeurological Sci
Mosquera-Sulbaran, Hernández-Fonseca, Tetracycline and viruses: a possible treatment for COVID-19?, Arch Virol
Na, Chong, Woo, Poria cocos ethanol extract and its active constituent, pachymic acid, modulate sleep architectures via activation of GABAA-ergic transmission in rats, J Biomed Trans Res
Ohe, Shida, Yamamoto, COVID-19 Treated with Minocycline and Saiko-keishi-to: A Case Report
Ohe, Shida, Yamamoto, Seki, Furuya, Successful treatment with minocycline and Saiko-keishito for COVID-19, J Clin Exp Invest
Ono, Takayama, Arita, Effectiveness of Japanese traditional medicine (Kamikihito and Saikokeishito) for treating long COVID: A prospective observational study, Front Med
Sodhi, Etminan, Therapeutic potential for tetracyclines in the treatment of COVID-19, Pharmacotherapy
Takayama, Namiki, Arita, Multicenter, randomized controlled trial of tra ditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients, Front Pharmacol
Takayama, Namiki, Odaguchi, Prevention and recovery of COVID-19 patients with Kampo medicine: review of case reports and ongoing clinical trials, Front Pharmacol
Yates, Newman, Oshry, Doxycycline treatment of high-risk COVID 19-positive patients with comorbid pulmonary disease, Ther Adv Respir Dis
Yuan, Yang, Ma, A systematic review of the active saikosaponins and extracts isolated from Radix Bupleuri and their applications, Pharm Biol
Zhao, Patankar, Tetracycline as an inhibitor to the coronavirus SARS-CoV-2
Zheng, Huang, Lai, Glycyrrhizic acid for COVID-19: findings of targeting pivotal inflammatory pathways triggered by SARS-CoV-2, Front Pharmacol
Zhou, Zhang, Liu, Anti-fatigue effect from Ginseng Radix et Rhizoma: a suggestive and promising treatment for long COVID, Acupuncture and Herbal Medicine
